BLUEFIN

Serial Number 99218525
630

Registration Progress

Application Filed
Jun 4, 2025
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

BLUEFIN

Basic Information

Serial Number
99218525
Filing Date
June 4, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
630
Status Date
Jun 4, 2025
Application
Pending
Classes
005 042

Rights Holder

Bluefin Biomedicine, Inc.

03
Address
32 Tozer Road
Beverly, MA 01915

Ownership History

Bluefin Biomedicine, Inc.

Original Applicant
03
Beverly, MA

Legal Representation

Attorney
Keith Toms, Esq.

Application History

2 events
Date Code Type Description
Jun 4, 2025 MAFR O APPLICATION FILING RECEIPT MAILED
Jun 4, 2025 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Antibodies for medical purposes; Diagnostic biomarker reagents for medical purposes; Protein arrays for medical diagnosis purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical purposes; Pharmaceutical preparations for the treatment of cancer, oncologic diseases and disorders, inflammation and immunity diseases and disorders, immunodeficiency diseases and disorders, genetic diseases and disorders, metabolic diseases and disorders, neurodegenerative diseases and disorders, kidney diseases and disorders, eye diseases and disorders, uveitis, glomerulosclerosis, glomerulonephritis, cardiovascular diseases and disorders
Class 042
Pharmaceutical research and development; Research and development services in the field of antibodies; Providing medical and scientific research information; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of biotechnology; Consulting services in the field of pharmacogenetics; Research and development in the field of biologics, namely, antibodies and peptides for the field of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; Research and development in the field of pharmaceuticals, biopharmaceuticals, and biotechnologies for the treatment of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; Research and development in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; Research and development in the field of proteomics, transcriptomics, and bioinformatics

Classification

International Classes
005 042

USPTO Documents

Loading USPTO documents...